Search Results - "Golshayan, A. R."

ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype by SMITH, A. M, FINDLAY, V. J, BANDURRAGA, S. G, KISTNER-GRIFFIN, E, SPRUILL, L. S, LIU, A, GOLSHAYAN, A. R, TURNER, D. P

“…Advanced disease accounts for the majority of prostate cancer-related deaths and androgen deprivation therapy (ADT) is the standard of care for these patients…”
Get full text

Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder by Chaudhary, U. B., Golshayan, A. R., Brisendine, A., Kraft, A. S., Clarke, H., Keane, T. E.

“…Abstract only 276 Background: Cisplatin-based neoadjuvant chemotherapy has shown survival advantage in patients (pts) with muscle-invasive bladder cancer. This…”
Get full text

Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib by Golshayan, A. R., Elson, P., Wood, L. S., Garcia, J. A., Dreicer, R., Rini, B. I.

“…Abstract only 5043 Background: An important goal of non-curative therapy for mRCC is tumor burden (TB) control. However, the impact of tumor burden…”
Get full text

Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features by Siddaiah, H., Golshayan, A. R., Elson, P., Zhou, M., Garcia, J. A., Bukowski, R. M., Rini, B. I.

“…Abstract only…”
Get full text

Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy by Golshayan, A. R., George, S., Heng, D. Y., Elson, P., Wood, L., Garcia, J. A., Aydin, H., Zhou, M., Bukowski, R. M., Rini, B. I.

“…Abstract only…”
Get full text

The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC) by Vaziri, S. A., Golshayan, A. R., Rini, B. I., Aydin, H., Zhou, M., Sercia, L., Wood, L., Ganapathi, M. K., Bukowski, R. M., Ganapathi, R.

“…Abstract only…”
Get full text

A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib by Heng, D. Y., Elson, P., Golshayan, A. R., Warren, M. A., Kollmannsberger, C., Chi, K. N., Cheng, T., North, S. A., Garcia, J. A., Bukowski, R. M., Rini, B. I.

“…Abstract only…”
Get full text

Characterization, resource use, and the economic impact of low-risk myelodysplastic syndrome (MDS) at an MDS specialty center by Sekeres, M. A., Jin, T., Maciejewski, J., Kalaycio, M. E., Brown, S., Advani, A., Golshayan, A.-R., Sobecks, R., Kattan, M. W.

“…Abstract only…”
Get full text

Impact of coronary sinus lead position on biventricular pacing: mortality and echocardiographic evaluation during long-term follow-up by Rossillo, Antonio, Verma, Atul, Saad, Eduardo B, Corrado, Andrea, Gasparini, Gianni, Marrouche, Nassir F, Golshayan, Ali Reza, McCurdy, Richard, Bhargava, Mandeep, Khaykin, Yaariv, Burkhardt, J David, Martin, David O, Wilkoff, Bruce L, Saliba, Walid I, Schweikert, Robert A, Raviele, Antonio, Natale, Andrea

“…Biventricular pacing is an established treatment for congestive heart failure. Whether the anatomic location of the coronary sinus (CS) lead affects outcomes…”
Get full text

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer by Golshayan, Ali R, Antonarakis, Emmanuel S

“…Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC)…”
Get full text

A30-2 Impact of the coronary sinus lead position for biventricular pacing: discrepancy between echocardiographic parameters and mortality by Rossillo, A., Gasparini, G., Saad, E. B., Marrouche, N. F., Corrado, A., Golshayan, A. R., Martin, D. O., Wilkoff, B. L., Saliba, W. I., Schweikert, R. A., Raviele, A., Natale, A.

Get full text